Author's response to reviews

Title: Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: case report

Authors:

Kazuhiko Nakano (nknkzhhk@jichi.ac.jp)
Kazumi Suzuki (s.kazu@jichi.ac.jp)
Tatsuo Morita (moritatu@jichi.ac.jp)

Version: 2 Date: 1 October 2011

Author's response to reviews: see over
October 1, 2011

Michael Kidd AM, M.D. & Ph.D.
Editor-in-Chief
Journal of Medical Case Reports
BioMed Central Ltd, Floor 6, 236 Gray’s Inn Road, London, WC1X 8HB
United Kingdom

Dear Dr. Michael:

I, along with my co-authors, would like to ask you to consider the attached manuscript entitled “Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: case report” for publication in Journal of Medical Case Reports as case report.

Sunitinib, an oral multitargeted tyrosine kinase inhibitor, is widely used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) and has a variety of adverse events. However, sunitinib-related acute cholecystitis has been reported in only 2 patients with GIST and RCC (clear cell subtype). We have experienced the third case of sunitinib-related acute cholecystitis in a patient with chromophobe RCC who developed serious condition. We described this case to pay attention to sunitinib-related acute cholecystitis which could be life-threatening albeit uncommon.

We believe that the findings of this report are relevant to the scope of your journal and will be of interest to its readership.

This manuscript has not been published or presented elsewhere in part or in entirely, and is not under consideration by another journal. All the authors have approved the manuscript and agree with submission to your esteemed journal. We obtained informed consent from the patient, and her anonymity was preserved. Financial support for this report was not provided. There are no conflicts of interest to declare.

I look forward to hearing from you at your earliest convenience.

Sincerely,

Kazuhiko Nakano, M.D.
Department of Urology, Jichi Medical University